Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PDGFRB rearrangements status confers therapeutic sensitivity to Imatinib in patients with Myeloproliferative Neoplasm.
Health Canada approved imatinib mesylate for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
This statement is based on a regulatory approval from the Health Canada:
GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.